| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tetrabutylammonium tetraphenylborate does not have a defined biological target as it is a chemical reagent rather than a pharmacologically active compound. Its function is physicochemical—it serves as a supporting electrolyte in electrochemical analysis and as a phase transfer catalyst. The tetraphenylborate anion can act as a weakly-coordinating anion, while the tetrabutylammonium cation is a hydrophobic phase transfer agent. In biological systems, quaternary ammonium salts can interact with cell membranes, but this is a non-specific effect. The compound is not designed for therapeutic use.
|
|---|---|
| ln Vitro |
Tetrabutylammonium tetraphenylborate is a biochemical reagent that can be utilized in studies pertaining to life sciences as an organic substance or biological material.
In vitro, tetrabutylammonium tetraphenylborate exhibits no pharmacological activity as it is a chemical reagent. Its utility is demonstrated in electrochemical analysis, where it serves as a supporting electrolyte with ≥99.0% purity. The compound is also used as a phase transfer catalyst in organic synthesis. In cell-based assays, the compound is not tested for biological activity. Its role is strictly chemical—providing ionic conductivity in electrochemical measurements and facilitating phase transfer in organic reactions. No specific pharmacological data are available. |
| ln Vivo |
Tetrabutylammonium tetraphenylborate is not a pharmacologically active agent and does not exhibit in vivo therapeutic activity. It is used as a chemical reagent for electrochemical analysis and phase transfer catalysis. The compound is not intended for human or animal exposure. It is used exclusively in laboratory and analytical settings. No therapeutic efficacy has been reported for this compound. The compound is not administered to animals in pharmacological studies and has no known physiological effects.
|
| Enzyme Assay |
In vitro assays for tetrabutylammonium tetraphenylborate focus on its electrochemical properties rather than receptor binding. A typical protocol involves preparing a solution of the compound in acetonitrile at concentrations of 0.01-0.1 M for use as a supporting electrolyte in cyclic voltammetry or other electrochemical measurements. The compound's purity (≥99.0% by NT) is verified by titration or HPLC. For phase transfer catalysis applications, the compound is dissolved in organic solvents and used to facilitate reactions between aqueous and organic phases. Quality control includes melting point determination (230-237°C) and HPLC purity analysis (>98.0%).
|
| Cell Assay |
Cell-based experiments are not performed with tetrabutylammonium tetraphenylborate itself, as it is a chemical reagent rather than a test compound for biological activity. When the compound is used in electrochemical or catalytic applications, it is not evaluated in cellular systems. Cytotoxicity studies are not standard for this compound as it is not intended for biological applications. The compound is handled with standard laboratory precautions for chemical reagents.
|
| Animal Protocol |
In vivo animal studies are not conducted with tetrabutylammonium tetraphenylborate, as it is a research reagent for chemical and electrochemical analysis. The compound is not used as a therapeutic test article and has no known pharmacological applications. Toxicological evaluations are not standard for this compound as it is not intended for human or animal exposure. It is used exclusively in laboratory and industrial settings.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of tetrabutylammonium tetraphenylborate are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 561.69, high lipophilicity due to four butyl chains, logP approximately 5-6), the compound would be expected to have very low oral bioavailability due to poor water solubility and high molecular weight. If absorbed, it would likely distribute extensively to lipid-rich tissues and be slowly eliminated. The compound may undergo metabolism via N-dealkylation. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for tetrabutylammonium tetraphenylborate indicate that it causes skin irritation (H315). The compound has a signal word of "Warning" and should be handled with appropriate personal protective equipment including gloves and safety glasses. The compound should be stored at room temperature (below 15°C in a cool, dry place). No acute toxicity, mutagenicity, or carcinogenicity data are available. The compound is not intended for drug, household, or other uses.
|
| Additional Infomation |
Tetrabutylammonium tetraphenylborate is a quaternary ammonium salt composed of a tetrabutylammonium cation and a tetraphenylborate anion. It is commonly used as a supporting electrolyte for electrochemical analysis (≥99.0%) and as a phase transfer catalyst. The compound is also known as TBATPB and Bu₄NBPh₄. It has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is physicochemical—providing ionic conductivity and facilitating phase transfer in chemical reactions.
|
| Molecular Formula |
C40H56BN
|
|---|---|
| Molecular Weight |
561.69
|
| Exact Mass |
561.45
|
| CAS # |
15522-59-5
|
| PubChem CID |
3084234
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
230-236ºC(lit.)
|
| LogP |
8.067
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
42
|
| Complexity |
418
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[N+](C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H].C1([B-](C2C([H])=C([H])C([H])=C([H])C=2[H])(C2C([H])=C([H])C([H])=C([H])C=2[H])C2C([H])=C([H])C([H])=C([H])C=2[H])C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
ZHCCBGAUZWZGQV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H20B.C16H36N/c1-5-13-21(14-6-1)25(22-15-7-2-8-16-22,23-17-9-3-10-18-23)24-19-11-4-12-20-24;1-5-9-13-17(14-10-6-2,15-11-7-3)16-12-8-4/h1-20H;5-16H2,1-4H3/q-1;+1
|
| Chemical Name |
tetrabutylazanium;tetraphenylboranuide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7803 mL | 8.9017 mL | 17.8034 mL | |
| 5 mM | 0.3561 mL | 1.7803 mL | 3.5607 mL | |
| 10 mM | 0.1780 mL | 0.8902 mL | 1.7803 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
